|
This resource has been retired and is no longer considered an AWMSG-endorsed resource. The resource underwent an assessment for review in March 2026. At that time members of the All Wales Prescribing Advisory Group (AWPAG) considered it appropriate to retire the resource. The content contained within the resource was considered to be out of date and, as other UK organisations offer suitable alternative guidance (e.g. NICE), AWPAG members considered it most appropriate for the resource to be retired at this time. If you think this resource should be reconsidered for review, please get in touch with AWTTC by emailing awttc@nhs.wales.uk. |
This guidance has been developed to help support healthcare professionals in the prescribing of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease. This document includes a comprehensive review of the evidence for SGLT-2 inhibitor use in type 2 diabetes mellitus in relation to cardiovascular and renal outcomes, outlines prescribing recommendations on the role of SGLT-2 inhibitors in this patient population and includes a one-page evidence summary for Welsh healthcare practitioners choosing an SGLT-2 inhibitor.
⇩ All Wales advice on sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 2 diabetes and cardiovascular disease 580KB (PDF) |
Published in September 2021
Retired June 2026
A separate one-page evidence summary for healthcare practitioners is also available: